NSCLC
Crizotinib shows in vitro activity and early evidence of clinical activity in ROS1-rearranged NSCLC.
Crizotinib shows in vitro activity and early evidence of clinical activity in <span class="gene" id="22215748-13-78-82">ROS1</span>-rearranged <span class="disease" id="22215748-13-94-99">NSCLC</span>.